What deworming medications and dosing regimens are recommended for children?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 5, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Deworming Medications for Children

For soil-transmitted helminth infections in children, albendazole 400 mg as a single oral dose is the first-line treatment for children aged >24 months, with ivermectin 200 μg/kg added for enhanced efficacy against Trichuris and Strongyloides. 1

Standard Dosing Regimens

Albendazole (First-Line)

  • Children >24 months: 400 mg single oral dose 1
  • Children 12-24 months: Discuss with expert before treatment 1
  • Repeat dosing: Consider repeating at 2 weeks for certain infections (e.g., Enterobius, Echinococcus) 1

Combination Therapy for Enhanced Efficacy

  • Albendazole 400 mg PLUS Ivermectin 200 μg/kg (single doses) for:
    • Empirical treatment of asymptomatic eosinophilia in children >24 months 1
    • Improved efficacy against Trichuris trichiura (cure rate increased to 75.2% vs 27.1% with albendazole alone) 2
    • Treatment of Strongyloides (prepatent or undetected infections) 1

Critical caveat: Exclude Loa loa infection before administering ivermectin in children who have traveled to endemic regions (Central/West Africa), as ivermectin can cause severe adverse reactions in loiasis 1

Alternative Agents

Mebendazole

  • Dosing: 500 mg single dose OR 100 mg twice daily for 3 days 1
  • Efficacy: Comparable to albendazole for Ascaris lumbricoides (98.69% egg reduction rate) but suboptimal for Trichuris (48.15% cure rate) and hookworm (49.32% cure rate) 3

Praziquantel (for Schistosomiasis)

  • Dosing: 25 mg/kg three times daily for 2-3 consecutive days 1
  • Timing: For acute schistosomiasis, repeat treatment at 8 weeks to treat residual worms after maturation 1

Helminth-Specific Considerations

Ascaris lumbricoides

  • Single-dose albendazole achieves 80.1% cure rate and 70.8% egg reduction rate 2
  • Both albendazole and mebendazole show >95% egg reduction rates 3

Trichuris trichiura

  • Major treatment challenge: Single-dose albendazole shows only 27.1% cure rate 2
  • Solution: Albendazole + ivermectin combination increases cure rate to 75.2% with 84.2% egg reduction 2
  • Mebendazole alone similarly suboptimal (48.15% cure rate) 3

Hookworm Species

  • Albendazole preferred: 93.44% egg reduction rate and 78.32% cure rate 3
  • Mebendazole less effective: 49.32% cure rate 3

Strongyloides stercoralis

  • Ivermectin 200 μg/kg is the treatment of choice 1
  • Can be combined with albendazole for empirical treatment 1

Important Clinical Pitfalls

Reinfection Rates

  • Critical limitation: In endemic areas, reinfection occurs rapidly—Ascaris infections return to baseline levels by 12-16 weeks post-treatment 4
  • This explains why mass deworming programs show minimal long-term nutritional or developmental benefits 5

Treatment Failure Recognition

  • Persistent symptoms or eosinophilia 2-4 weeks post-treatment suggests:
    • Treatment failure (particularly with Trichuris) 2
    • Reinfection 4
    • Alternative diagnosis (consider schistosomiasis, strongyloidiasis) 1

Schistosomiasis Timing

  • Eggs and immature schistosomulae are resistant to praziquantel 1
  • Must repeat treatment at 8 weeks to target mature worms 1

Mass Deworming Programs vs Individual Treatment

Individual Treatment (Known Infection)

  • Children with confirmed helminth infection may gain 0.2-1.3 kg additional weight over 1-6 months with treatment 5
  • Justifies treatment in symptomatic or heavily infected children 5

Community Mass Deworming

  • Evidence shows minimal benefit: No significant effect on average weight gain (0.04 kg difference), hemoglobin, cognition, school performance, or mortality in endemic area programs 5
  • WHO still recommends biannual treatment in high-prevalence areas for morbidity reduction, despite limited evidence for broader health benefits 5

Special Populations

HIV-Infected Children

  • Same dosing regimens apply 1
  • Consider empirical treatment for eosinophilia, as helminth co-infection is common 1

Immunocompromised Children

  • Higher risk for disseminated strongyloidiasis—ensure adequate treatment with ivermectin 1
  • Consider longer treatment courses or expert consultation 1

Related Questions

What are the possible causes and recommended evaluation for a 4‑month‑old female infant who cannot lift her arm above her head?
What is the recommended approach for conducting a well‑child visit for an 8‑year‑old child?
How should I manage a neonate with an oxygen saturation of 80%?
How should nasal congestion be managed in a 1‑month‑old infant?
Is it normal for a 9‑month‑old infant to have no erupted primary teeth, and what follow‑up evaluation is recommended?
What is the appropriate next step for a patient with a normal comprehensive metabolic panel and mildly elevated total protein?
In a 34-year-old female truck driver with a BMI of 29 and office blood pressure of 136/84 mm Hg on two separate visits, after recommending lifestyle modifications, what is the most appropriate next step in managing her blood pressure?
What is the recommended diagnostic workup and treatment approach for suspected central venous stenosis in patients with long‑term hemodialysis catheters, prior central line placements, or thoracic radiation?
What is the appropriate micro‑dosing (titration) regimen of tirzepatide for a 68‑year‑old obese male with prior atrial‑fibrillation ablations, a permanent pacemaker, a Watchman device, chronic obstructive pulmonary disease, and chronic heart failure?
How should I evaluate and manage a patient presenting with headache and dizziness?
What is the recommended initial treatment and management plan for hyperthyroidism, including antithyroid drug dosing, beta‑blocker use, monitoring, and definitive therapy options?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.